Perry Drug Recalls Testosterone Cyp Syringes Due to Sterility Concerns
Perry Drug Inc. is recalling Testosterone Cyp 200 mg/mL syringes due to quality control issues affecting sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the hazard involves a lack of sterility assurance in a sterile injectable product, which poses a significant risk of serious injury or infection.
Plain-English summary
Perry Drug Inc. is recalling Testosterone Cyp 200 mg/mL Sesame Inj., 4Ml Syringes, Compounded Rx, NDC 88888-7906-71. The recall involves all lots of sterile products compounded by the pharmacy that are within their expiry date.
The recall was initiated due to concerns associated with quality control procedures that present a potential risk to sterility assurance. These concerns were observed during a recent FDA inspection.
The affected products were distributed in Kansas and Missouri. Consumers should stop using the recalled product and contact their healthcare provider or pharmacist for further instructions.
The recalled product
- Product
- Testosterone Cyp 200 mg/mL Sesame Inj., 4Ml Syringes, Compounded Rx, Perry Drug Compounding Pharmacy, Overland Park, KS --- NDC 88888-7906-71
- Manufacturer
- Perry Drug Inc.
- Affected units
- 1
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- 141013DD
- 11/13/14
Distribution
Part of a larger recall action
This product is one of 17 recalled by Perry Drug Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 17 products in this recall →Related recalls
Same manufacturer · Perry Drug Inc.
See all →- SeverePerry Drug Recalls Cyclosporine Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2014-12-03
- SeverePerry Drug Recalls Tri-mix Antidote Syringes Due to Sterility Concerns
FDA (Drugs) · 2014-12-03
- SeverePerry Drug Recalls HCG Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-12-03
- SeverePerry Drug Recalls Methyl B12 Syringes Due to Sterility Concerns
FDA (Drugs) · 2014-12-03
- SeverePerry Drug Recalls Phenylephrine Syringes Due to Sterility Concerns
FDA (Drugs) · 2014-12-03
Same hazard · sterility failure
See all →- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22
Similar recalls
- ModerateUniversity Compounding Pharmacy Recalls Testosterone CYP Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- SevereWestern Drug Recalls Testosterone CYP Injections Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereMedaus Recalls Testosterone Cyp 200 mg/mL Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- Severe
- SevereGreen Valley Drugs Recalls Testosterone Cypionate Injection Due to Sterility Concerns
FDA (Drugs) · 2013-05-22
- SevereClinical Specialties Compounding Pharmacy Recalls Testosterone and Estradiol Injection
FDA (Drugs) · 2013-07-10